Tinzaparin Pharmacokinetics in Patients with Cancer: A Comparative Modeling Study.
Xavier Delavenne, Jean Escal, Dominique Helley et al.
✦ AI-curated · Sources linked
In 30 seconds
This prospective, multicenter comparative trial used population pharmacokinetic modeling to compare therapeutic-dose tinzaparin in patients with and without cancer. The analysis included 333 patients, including 46 matched cancer and non-cancer patients. A one-compartment model with first-order absorption best described tinzaparin pharmacokinetics. Body weight was associated with volume of distribution, and creatinine clearance with clearance and anti-Xa activity. No significant differences in anti-Xa activity exposure were observed between matched groups on day 1 or at steady state.
Key findings
- Among 46 matched cancer and non-cancer patients, anti-Xa activity exposure did not differ significantly on day 1 or at steady state.
- Body weight was associated with tinzaparin volume of distribution.
- Creatinine clearance was associated with tinzaparin clearance and anti-Xa activity.
Why it matters
The findings suggest that cancer status alone was not associated with different tinzaparin anti-Xa exposure in the matched patients studied. The observed relationships with body weight and renal function help identify factors relevant to pharmacokinetic variability, while the authors note that further work is needed to clarify renal function’s role in dosing.
What to keep in mind
The cancer and non-cancer comparison was based on 46 matched patients, limiting the evidence for differences between groups.